IRVINE, Calif., Jan. 20 /PRNewswire-FirstCall/ -- ChromaDex Corporation (OTC Bulletin Board: CDXC), a world leader in the development of phytochemical and botanical reference standards, announced the addition of a new Agilent 6520 Quadrupole Time-of-Flight (Q-TOF) Mass Spectrometer to its lineup of analytical capabilities. Controlled by the Agilent MassHunter software, this unit provides unparalleled mass accuracy, mass resolution, sensitivity, in-spectrum dynamic range and speed. This addition complements the vast array of analytical instrumentation that ChromaDex has available to solve the tough problems of its customers.
"ChromaDex has been a good customer of Agilent over the years. We are very pleased that they selected the Agilent Q-TOF Mass Spec to meet the expanding needs of their clients," said Kevin Larson, Agilent Account Manager.
"This is a further demonstration of our ongoing commitment to the industries we serve to be the one source for their analytical needs. The capability of our new LC/MS adds a new dimension to the service we can provide our customers," said Frank Jaksch, CEO and Co-Founder of ChromaDex. "We will now be able to accurately identify unknown, trace levels of compounds or precisely assess the levels of a particular compound in our clients' products."
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is the world's premier measurement company and a technology leader in communications, electronics, life sciences and chemical analysis. The company's 17,000 employees serve customers in more than 110 countries. Agilent had net revenues of $4.5 billion in fiscal 2009. Information about Agilent is available on the Web at www.agilent.com.
ChromaDex is a world leader in the development of phytochemical and botanical reference standards and the creation of associated intellectual property. ChromaDex is committed to sustainable, "green chemistry" and provides the dietary supplement, food, beverage, nutraceutical and cosmetic industries with the analytical tools, products, and services to meet the regulatory, quality, efficacy and safety standards for their products.
Any statements that are not historical facts contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the effect of economic conditions both nationally and internationally, ability to protect our intellectual property rights, impact of any litigation or infringement actions brought against us, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, the ability to complete transactions, and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.